Complete financial analysis of Bukwang Pharmaceutical Co., Ltd. (003000.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bukwang Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- BankInvest – Danske Aktier KL (BAIDKAA.CO) Income Statement Analysis – Financial Results
- Gansu Yatai Industrial Developent Co., Ltd. (000691.SZ) Income Statement Analysis – Financial Results
- Twelve Seas Investment Company II (TWLV) Income Statement Analysis – Financial Results
- Smart Decision, Inc. (SDEC) Income Statement Analysis – Financial Results
- clearvise AG (ABO.DE) Income Statement Analysis – Financial Results
Bukwang Pharmaceutical Co., Ltd. (003000.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bukwang.co.kr
About Bukwang Pharmaceutical Co., Ltd.
Bukwang Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. It manufactures oral solid dosage forms, injections, oral solutions, external-use solutions, and ointments. The company offers products in various therapeutic areas, including liver disease treatments, such as Levovir and Legalon; diabetic complication products comprising Dexid and Thioctacid; CNS disorder drugs consisting of Lonasen, Ixel, and Orfil; and respiratory disease treatments, which comprise Azeptin and Asima. It also provides OTC products; toothpastes, and hair and skin care goods; and nutritional supplements. In addition, the company offers products for antihistamines, hepatitis and gastrointestinal, sedative and antidote, anti-cancer, thyroid and osteoporosis, diabetes, obstetrics, urinogenital, cardiovascular, dermatology, obesity, pain relief, and muscle relaxant. Further, it provides products for bruises, skin and mucous membrane, rhinitis, cold symptoms, cough, phlegm and asthma, rheumatoid arthritis, osteoarthritis, pain caused by cold and fever, dysmenorrhea, NSAIDs, inflammation, joint inflammation, tinea pedis, infected wounds, dermatitis, antivirals-herpes, eczema, diarrhea, dyspepsia, sense of distension, anti-histamine, anti-ulcer, constipation, anemia, pregnant multivitamins, candidiasis, athlete's foot, onychomycosis, stomatitis, pimple, acne, physical fatigue, neuralgia, myalgia, and arthralgia. Additionally, the company offers medicines for period of lactation, rickets, night blindness, varicose vein, and sputum; and quasi drugs and medical devices, as well as health functional food. It also develops anti-diabetes compound with Melior Pharmaceuticals; and anti-cancer drugs with LSK BioPartners, as well as cell therapies using adult stem cells, as well as holds a license for a novel candidate to treat movement disorder in Parkinson's disease patients. The company was founded in 1960 and is based in Seoul, South Korea.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 125.93B | 190.91B | 182.49B | 169.66B | 168.19B | 194.22B | 150.74B | 138.62B | 142.13B | 141.69B | 130.79B | 147.53B | 101.22B | 180.62B | 170.81B | 161.58B | 155.67B | 137.52B |
Cost of Revenue | 75.88B | 111.48B | 106.73B | 98.02B | 83.94B | 79.22B | 70.11B | 62.33B | 59.29B | 60.45B | 60.04B | 67.93B | 44.96B | 74.87B | 72.65B | 65.27B | 58.85B | 60.22B |
Gross Profit | 50.05B | 79.43B | 75.76B | 71.64B | 84.25B | 115.01B | 80.63B | 76.29B | 82.84B | 81.24B | 70.76B | 79.59B | 56.26B | 105.75B | 98.16B | 96.31B | 96.82B | 77.30B |
Gross Profit Ratio | 39.74% | 41.61% | 41.51% | 42.23% | 50.09% | 59.21% | 53.49% | 55.04% | 58.29% | 57.33% | 54.10% | 53.95% | 55.58% | 58.55% | 57.46% | 59.61% | 62.20% | 56.21% |
Research & Development | 38.93B | 24.27B | 22.46B | 18.03B | 17.31B | 24.64B | 25.07B | 18.68B | 14.88B | 10.23B | 7.24B | 8.90B | 6.11B | 6.58B | 4.52B | 4.70B | 4.26B | 2.88B |
General & Administrative | 4.47B | 5.05B | 4.43B | 4.48B | 7.19B | 6.81B | 6.61B | 6.54B | 6.02B | 5.84B | 6.48B | 8.25B | 6.53B | 12.48B | 10.05B | 9.37B | 8.82B | 7.69B |
Selling & Marketing | 17.64B | 14.77B | 9.06B | 10.79B | 15.05B | 13.33B | 9.89B | 12.18B | 8.80B | 9.99B | 9.79B | 13.49B | 13.32B | 10.85B | 12.58B | 14.37B | 12.93B | 13.14B |
SG&A | 48.61B | 19.82B | 13.49B | 15.26B | 22.24B | 20.13B | 16.50B | 18.72B | 14.82B | 15.83B | 16.26B | 21.74B | 19.85B | 23.33B | 22.63B | 23.73B | 21.75B | 20.82B |
Other Expenses | 1.11B | 35.56B | 34.18B | 34.32B | 35.16B | 35.11B | 280.72M | 8.10B | 2.82B | -461.33M | -460.21M | 220.45M | 13.56M | -924.17M | -929.24M | -460.00M | 267.58M | -242.75M |
Operating Expenses | 87.54B | 79.66B | 70.14B | 67.61B | 74.71B | 79.88B | 72.95B | 67.75B | 59.56B | 52.88B | 47.76B | 58.15B | 47.75B | 66.56B | 59.08B | 57.06B | 54.36B | 50.80B |
Cost & Expenses | 163.43B | 191.14B | 176.87B | 165.63B | 158.66B | 159.10B | 143.07B | 130.08B | 118.84B | 113.33B | 107.80B | 126.08B | 92.71B | 141.43B | 131.73B | 122.32B | 113.21B | 111.03B |
Interest Income | 3.08B | 1.44B | 264.34M | 1.31B | 2.05B | 6.97B | 425.22M | 754.18M | 1.32B | 1.99B | 1.84B | 2.82B | 844.26M | 951.70M | 961.23M | 2.01B | 2.76B | 1.21B |
Interest Expense | 3.81B | 1.76B | 1.41B | 1.51B | 90.85M | 0.00 | 0.00 | 1.52M | 0.00 | 5.00 | 292.55M | 2.01B | 1.00B | 2.18B | 2.32B | 1.60B | 7.00K | 0.00 |
Depreciation & Amortization | 4.29B | 5.12B | 4.84B | 6.16B | 5.84B | 6.88B | 6.10B | 5.70B | 5.13B | 5.68B | 7.63B | 7.38B | 5.79B | 7.05B | 3.05B | 4.45B | 4.36B | 3.49B |
EBITDA | -31.47B | 5.79B | 11.40B | 2.21B | 5.35B | 197.93B | 20.98B | 26.73B | 28.41B | 34.03B | 30.63B | 32.63B | 14.30B | 47.39B | 42.23B | 45.62B | 50.06B | 29.98B |
EBITDA Ratio | -24.99% | 3.49% | 5.41% | 3.97% | 10.11% | 20.20% | 9.05% | 19.12% | 17.49% | 24.02% | 25.49% | 22.15% | 15.36% | 25.78% | 24.78% | 28.24% | 32.04% | 21.55% |
Operating Income | -37.50B | 1.55B | 5.62B | 583.65M | 9.54B | 35.13B | 7.68B | 8.54B | 23.29B | 28.36B | 22.99B | 21.44B | 7.35B | 39.19B | 39.08B | 39.25B | 42.46B | 26.50B |
Operating Income Ratio | -29.78% | 0.81% | 3.08% | 0.34% | 5.67% | 18.09% | 5.09% | 6.16% | 16.38% | 20.01% | 17.58% | 14.53% | 7.26% | 21.70% | 22.88% | 24.29% | 27.28% | 19.27% |
Total Other Income/Expenses | -2.07B | -2.58B | -1.83B | -12.33B | -10.90B | 155.93B | 5.22B | 12.49B | 8.55B | 1.24B | 1.04B | 1.79B | 155.88M | -1.04B | -2.21B | 313.04M | 3.23B | 1.14B |
Income Before Tax | -39.57B | -1.03B | 3.79B | -8.30B | -1.36B | 191.06B | 14.88B | 21.03B | 31.84B | 29.60B | 25.58B | 23.24B | 7.51B | 38.15B | 36.86B | 39.57B | 45.69B | 27.64B |
Income Before Tax Ratio | -31.42% | -0.54% | 2.08% | -4.89% | -0.81% | 98.37% | 9.87% | 15.17% | 22.40% | 20.89% | 19.56% | 15.75% | 7.42% | 21.12% | 21.58% | 24.49% | 29.35% | 20.10% |
Income Tax Expense | -5.16B | 3.22B | 6.58B | 1.81B | 6.07B | 45.40B | 3.79B | 5.22B | 6.70B | 5.98B | 6.05B | 6.72B | 1.10B | 10.76B | 8.99B | 8.95B | 12.67B | 8.09B |
Net Income | -31.33B | -4.25B | -2.80B | -10.10B | -7.43B | 145.67B | 11.09B | 15.81B | 25.14B | 23.62B | 19.53B | 16.51B | 6.41B | 27.39B | 27.87B | 30.88B | 32.82B | 19.55B |
Net Income Ratio | -24.88% | -2.23% | -1.53% | -5.96% | -4.42% | 75.00% | 7.36% | 11.40% | 17.69% | 16.67% | 14.93% | 11.19% | 6.33% | 15.17% | 16.32% | 19.11% | 21.08% | 14.21% |
EPS | -457.67 | -62.07 | -40.85 | -147.23 | -103.65 | 2.61K | 161.84 | 222.20 | 354.19 | 336.67 | 275.21 | 233.91 | 93.42 | 376.05 | 380.37 | 423.24 | 466.46 | 282.67 |
EPS Diluted | -457.67 | -62.07 | -40.85 | -147.23 | -103.65 | 2.61K | 161.84 | 222.20 | 353.69 | 336.67 | 275.21 | 233.91 | 93.42 | 376.05 | 380.37 | 423.24 | 466.46 | 282.67 |
Weighted Avg Shares Out | 68.45M | 68.45M | 68.46M | 68.63M | 71.73M | 55.73M | 68.53M | 71.14M | 70.98M | 70.15M | 70.97M | 70.59M | 68.71M | 72.85M | 73.28M | 72.96M | 70.36M | 69.15M |
Weighted Avg Shares Out (Dil) | 68.45M | 68.45M | 68.46M | 68.63M | 71.73M | 55.73M | 68.53M | 71.14M | 71.08M | 70.15M | 70.97M | 70.59M | 68.71M | 72.85M | 73.28M | 72.96M | 70.36M | 69.15M |
Source: https://incomestatements.info
Category: Stock Reports